Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Enrolling By Invitation
18 years - 39 years
All
Phase
3
10 participants needed
1 Location
Brief description of study
The first purpose of this study is to test the safety of the addition of a drug called inotuzumab to the usual chemotherapy drugs used for adolescent young adults (ages 18-39). Inotuzumab is investigational and is not FDA-approved. Additionally,this study is to compare any good and bad effects of using inotuzumab along with the usual chemotherapy treatment for your cancer to using the usual treatment alone.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Acute Lymphoblastic Leukemia,Leukemia
-
Age: 18 years - 39 years
-
Gender: All
Male and Female, Ages 18-39, Diagnosed with CD-22 positive B-cell acute lymphoblastic leukemia
Updated on
30 Jul 2025.
Study ID: 832340
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
